MICROWAVE ABLATION
FOR COLORECTAL LIVER METASTASES
For patients with limited colorectal liver metastases that cannot be surgically removed, microwave ablation offers durable local control as part of a multi-modal treatment plan combining ablation, chemotherapy, and selective use of surgery.
analyticsAt a Glance
- check_circlePhase III CLOCC trial: ablation + chemo improved OS vs chemo alone in unresectable CRC liver mets
- check_circle5-year survival 30โ45% in well-selected oligometastatic patients
- check_circleBest for โค5 lesions, each <3 cm, in patients not suitable for surgery
- check_circleCombined with systemic chemotherapy as part of multi-modal treatment
Why Liver Is the Critical Site in Colorectal Cancer
Roughly 50% of colorectal cancer patients eventually develop liver metastases. For some, the metastases are surgically removable โ and surgical resection can be curative, with 5-year survival of 30โ60% in well-selected cases. But many patients have metastases that are unresectable due to location, multifocality, or insufficient liver reserve. For these patients, microwave ablation has become a key part of the treatment arsenal.
โIn colorectal cancer with liver-limited disease, local control of liver metastases matters. Long-term survival depends on whether all liver disease can be eliminated โ by surgery, ablation, or the two combined.โ
The Surgical Resection Standard
For colorectal liver metastases that can be safely removed with negative margins and adequate remaining liver, surgical resection (hepatectomy or wedge resection) is the standard curative-intent treatment. 5-year survival of 30โ60% is achievable in selected patients. About 20โ30% of patients with liver mets are surgical candidates at presentation.
The Unresectable Majority
Most patients with colorectal liver metastases are not initially surgical candidates due to multifocal disease, central location, insufficient remaining liver, comorbidities, or extrahepatic involvement. For these patients, systemic chemotherapy ยฑ targeted therapy ยฑ local ablation forms the treatment strategy.
When MWA Is Used in Colorectal Liver Metastases
MWA fits into the CRC liver metastases treatment paradigm at several distinct points. Understanding each scenario clarifies when ablation is the right choice.
Unresectable Limited-Disease (Oligometastases)
Patients with up to 5 liver lesions, each <3 cm, that cannot be safely surgically removed โ but where local control of all liver disease is feasible with ablation. MWA combined with systemic chemotherapy is the standard approach. Curative-intent outcomes are realistic in this setting.
After Liver Resection (Salvage)
Patients who have already had liver surgery and developed new metastases. Repeat surgery may be unfeasible due to insufficient remaining liver. MWA provides local control of new lesions while preserving liver tissue, allowing continued multi-modal treatment.
Combined Surgery + Ablation Strategy
For patients with bilateral disease where one side is surgically removable but the other has small additional lesions, surgery on one side combined with MWA on the other can achieve complete liver disease elimination โ neither approach alone would suffice.
Medical High-Risk Patients
Patients who would be surgical candidates anatomically but whose comorbidities (cardiac disease, frailty, advanced age) make liver resection too risky. MWA offers a less morbid path to similar local disease control.
Test of Time / Re-evaluation
For patients with rapidly evolving systemic disease where the indolence of the liver metastases is unclear, MWA can provide local control while systemic therapy continues โ allowing time to assess whether the patient remains liver-dominant or develops more widespread disease.
Patient Selection: Who Is a Good MWA Candidate
Selection drives outcomes substantially. The patients who benefit most from MWA share common characteristics.
| Factor | Strong Candidate | Less Strong / Alternative Approaches |
|---|---|---|
| Number of Liver Lesions | Up to 5 lesions; ideally โค3 | Diffuse multifocal disease (>10 lesions) typically not ideal |
| Largest Lesion Size | <3 cm โ best outcomes; up to 5 cm with technique adaptation | >5 cm โ typically need resection or TACE/MWA combination |
| Extrahepatic Disease Status | No extrahepatic disease, or limited stable extrahepatic disease | Extensive extrahepatic disease โ systemic therapy priority |
| Performance Status | ECOG 0โ1 | ECOG 3โ4 |
| Liver Reserve | Adequate functional liver; no portal hypertension | Severe hepatic dysfunction or extensive prior surgery |
| Lesion Location | Accessible from skin; safe distance from bowel, gallbladder, major bile ducts | Subcapsular near bowel, or central with bile duct proximity |
| Response to Systemic Therapy | Disease control or response on chemotherapy | Rapid progression on multiple chemotherapy lines |
| Tumour Biology | Classical metachronous (developing after primary surgery) | Synchronous high-volume hepatic-dominant disease may favour surgery if feasible |
The CLOCC Trial: Evidence Supporting Ablation in Unresectable CRC Liver Mets
The CLOCC (Chemotherapy + Local Ablation versus Chemotherapy Alone) trial โ EORTC 40004 โ was the landmark phase III trial establishing the role of ablation in unresectable colorectal liver metastases.
Trial Design
CLOCC randomised 119 patients with unresectable colorectal liver metastases (โค9 lesions, each โค4 cm) to receive systemic chemotherapy (FOLFOX) alone vs systemic chemotherapy plus local ablation (primarily RFA, with surgical resection allowed in selected cases). The trial used RFA rather than MWA โ but the principle of adding local ablation to systemic therapy is applicable to both.
Key Results
At long-term follow-up, the ablation + chemotherapy arm showed substantially better outcomes than chemotherapy alone: 8-year overall survival of 35.9% vs 8.9%, and median overall survival of 45.6 months vs 40.5 months. The benefit was particularly pronounced for long-term survival โ showing that local control of liver disease has lasting impact on outcomes.
Why This Matters
CLOCC established that for selected patients with unresectable colorectal liver metastases, combining local ablation with systemic chemotherapy meaningfully improves outcomes. Modern practice has shifted to MWA in most centres because of its technical advantages, but the underlying principle โ local control matters in oligometastatic CRC โ remains a cornerstone of treatment.
Limitations of the Evidence
CLOCC enrolled relatively well-selected patients and used RFA rather than MWA. Modern systemic therapy (FOLFOX/FOLFIRI + biological agents like bevacizumab or cetuximab/panitumumab) has improved beyond what CLOCC used. The magnitude of ablation benefit in modern multi-modal regimens may differ. Despite these caveats, CLOCC remains the cornerstone phase III evidence supporting local ablation in this setting.
Outcomes Data: MWA in Colorectal Liver Metastases
Published outcomes from major series of MWA for colorectal liver metastases in oligometastatic disease.
5-Year Overall Survival by Patient Selection
Long-term survival depends heavily on patient selection โ number of lesions, size, systemic disease status, and treatment response.
- Oligometastatic (1โ3 lesions), Good Response to Chemo40โ50%
- Limited Multifocal (4โ5 lesions)25โ35%
- More Extensive (6โ10 lesions)15โ25%
Local Tumour Progression at 2 Years โ CRC Liver Mets
MWA produces consistently lower local recurrence rates than RFA in colorectal liver metastases, particularly in larger lesions and those near vessels.
- MWA โ Lesions <2 cm8โ15%
- MWA โ Lesions 2โ3 cm15โ25%
- RFA โ Lesions 2โ3 cm25โ40%
The MWA Pathway for CRC Liver Metastases
A typical patient journey from referral through treatment and long-term follow-up.
- 1
Step 1: Multi-Disciplinary Team Review
Surgical oncologist, interventional radiologist, medical oncologist, and radiologist review imaging and disease history. Discuss resectability, ablation candidacy, and systemic therapy plans. Determine the right combination for this patient.
- 2
Step 2: Systemic Chemotherapy
Most patients receive systemic chemotherapy before ablation โ typically FOLFOX or FOLFIRI ยฑ biological agent. This treats microscopic disease throughout the body and may reduce visible lesion size before ablation, improving complete ablation rates.
- 3
Step 3: Restaging and Ablation Planning
After systemic therapy, restaging imaging assesses response and confirms ablation candidacy. The ablation plan accounts for lesion size, location, and number โ including whether multiple sessions are needed.
- 4
Step 4: MWA Procedure(s)
CT-guided or ultrasound-guided percutaneous MWA. Multiple lesions can often be ablated in a single session; very widespread or complex distribution may require staged sessions over weeks. Most patients are discharged same-day or after one overnight observation.
- 5
Step 5: Continued Systemic Therapy
Most patients continue systemic chemotherapy after ablation. The exact regimen depends on prior treatment response and the patient's tolerance. Maintenance therapy may continue indefinitely or until disease progression.
- 6
Step 6: Long-Term Surveillance
Imaging surveillance every 3 months for the first 2 years, then every 6 months. CEA monitoring. New lesions are addressed with repeat MWA, resection, or other interventions as appropriate.
Related Treatments & Resources
Explore the full microwave ablation knowledge base.
- What Is Microwave Ablation? A Patient Introduction
- MWA vs RFA: Which Ablation Is Right for Your Tumour?
- Microwave Ablation for Liver Cancer (HCC): Evidence and Outcomes
- Microwave Ablation for Lung Cancer: NSCLC and Pulmonary Metastases
- Colorectal Cancer โ Condition Page
- Microwave Ablation โ Full Treatment Page
Frequently Asked Questions
Common questions about microwave ablation for colorectal liver metastases.
About the Treatment
Can MWA cure colorectal liver metastases?
For well-selected oligometastatic patients (โค3 small lesions, no extrahepatic disease, good response to systemic therapy), MWA combined with chemotherapy can achieve long-term disease-free survival in 30โ45% of patients at 5 years. Whether this represents "cure" depends on definition โ most oncologists consider these patients potentially curable, though late recurrences can occur. For more advanced disease, MWA contributes to disease control rather than cure.
Should I have surgery instead of MWA?
If your liver metastases are surgically resectable with negative margins and adequate remaining liver, resection is the standard of care with the longest evidence base. MWA is preferred when resection is not feasible due to lesion distribution, central location, insufficient remaining liver, or patient comorbidities. The multi-disciplinary team determines which is the better option in your specific case.
Do I still need chemotherapy if I have MWA?
Yes, in nearly all cases. Colorectal cancer treatment is fundamentally a systemic disease management problem. Even after complete local treatment of liver lesions, microscopic disease elsewhere drives recurrence. Systemic chemotherapy ยฑ biological agents is essential before, alongside, or after MWA. MWA addresses what we can see; chemotherapy addresses what we cannot.
Treatment Planning
How many MWA sessions will I need?
Depends on the number, size, and distribution of liver lesions. A single session can often address up to 4โ5 lesions in different parts of the liver. Patients with more extensive disease may need 2โ3 staged sessions weeks apart. New lesions developing during follow-up may require repeat MWA in the future โ multiple sessions over years are common.
What if my disease progresses despite MWA?
Disease progression after MWA can be addressed in several ways depending on the pattern: new liver lesions may be treated with repeat MWA; extrahepatic progression typically requires changes to systemic therapy; bulky liver progression may need TACE, TARE, or palliative care. The multi-disciplinary team adapts the plan based on how disease evolves.
How does CancerFax help with CRC liver mets treatment?
CancerFax reviews your imaging, treatment history, and biomarker results to assess MWA candidacy. We coordinate review with experienced centres offering integrated CRC liver mets care โ combining surgery, ablation, and systemic therapy. We provide transparent cost estimates and arrange travel logistics for international patients. Our recommendations weigh resection, ablation, and combined approaches honestly.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Considering MWA for Colorectal Liver Metastases?
Upload your medical records โ recent imaging, pathology, prior treatment history, CEA levels, and any prior liver surgery details. Our interventional and GI oncology team will review your case and identify the right combination of surgery, ablation, and systemic therapy.
This content is for informational purposes only. Treatment of colorectal liver metastases requires multi-disciplinary team evaluation. Always consult your treating oncology team before making decisions.